ImClone System's finance-meister is jumping ship, the company announced. And no, it's not your imagination--Ana Stancic's departure will make ImClone the sixth biopharma company to lose its finance chief in recent months. There's also Pfizer (which announced its new CFO yesterday), Wyeth, AstraZeneca, Amgen, and Merck.
Stancic's departure will follow the entrance of new ImClone CEO John Johnson, who starts Monday. The company has been getting by on interim chief execs--including a three-person executive committee, which took over last year--since 2005.
- read the report from The Wall Street Journal